Madrigal Rezdiffra Two-Year Data Shows Marked Liver Stiffness Reduction in MASH Cirrhosis
Madrigal Pharmaceuticals presented two-year data showing its therapy Rezdiffra improved liver stiffness and fibrosis biomarkers in patients with compensated MASH cirrhosis. These sustained improvements demonstrate that manufactured biologics can reverse chronic organ damage and bolster Madrigal’s therapeutic pipeline potential.
1. Two-Year Data for Rezdiffra
Madrigal reported that Rezdiffra produced statistically significant reductions in liver stiffness measurements and key fibrosis biomarkers over a 24-month follow-up in patients with compensated MASH cirrhosis. The therapy maintained a favorable safety profile throughout the study, indicating durable reversal of chronic liver damage in a patient population with limited treatment options.
2. Implications for Regulatory Approval and Market Position
These robust long-term results may serve as pivotal evidence for regulatory filings, potentially accelerating Rezdiffra’s approval timeline in MASH cirrhosis. By validating a scalable manufactured biologic, Madrigal strengthens its competitive positioning within the regenerative medicine landscape and enhances its prospects for future liver disease indications.